Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1988 Jun;32(6):877–881. doi: 10.1128/aac.32.6.877

Daptomycin (LY146032) treatment of experimental enterococcal endocarditis.

L M Bush 1, J A Boscia 1, D Kaye 1
PMCID: PMC172299  PMID: 2843085

Abstract

This study compared daptomycin (LY146032) with penicillin G procaine and vancomycin without and with gentamicin for treatment of experimental enterococcal endocarditis. The strain of Streptococcus (Enterococcus) faecalis used in this study was killed by daptomycin in vitro in broth but not in serum. In rabbits treated for 3 days, daptomycin significantly reduced bacterial counts of vegetations compared with no therapy but was significantly less effective than penicillin G procaine or vancomycin. Daptomycin-gentamicin significantly reduced bacterial counts of vegetations compared with daptomycin alone but was significantly less effective than vancomycin plus gentamicin. The efficacy of daptomycin-gentamicin did not differ significantly from that of penicillin G procaine-gentamicin. The lack of enterococcal killing by daptomycin alone in serum and in experimental endocarditis is probably related to the high protein binding of the agent.

Full text

PDF
877

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Carrizosa J., Kaye D. Antibiotic synergism in enterococcal endocarditis. J Lab Clin Med. 1976 Jul;88(1):132–141. [PubMed] [Google Scholar]
  2. Durack D. T., Petersdorf R. G. Chemotherapy of experimental streptococcal endocarditis. I. Comparison of commonly recommended prophylactic regimens. J Clin Invest. 1973 Mar;52(3):592–598. doi: 10.1172/JCI107220. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Eliopoulos G. M., Willey S., Reiszner E., Spitzer P. G., Caputo G., Moellering R. C., Jr In vitro and in vivo activity of LY 146032, a new cyclic lipopeptide antibiotic. Antimicrob Agents Chemother. 1986 Oct;30(4):532–535. doi: 10.1128/aac.30.4.532. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Fass R. J., Helsel V. L. In vitro activity of LY146032 against staphylococci, streptococci, and enterococci. Antimicrob Agents Chemother. 1986 Nov;30(5):781–784. doi: 10.1128/aac.30.5.781. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Jones R. N., Barry A. L. Antimicrobial activity and spectrum of LY146032, a lipopeptide antibiotic, including susceptibility testing recommendations. Antimicrob Agents Chemother. 1987 Apr;31(4):625–629. doi: 10.1128/aac.31.4.625. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Mederski-Samoraj B. D., Murray B. E. High-level resistance to gentamicin in clinical isolates of enterococci. J Infect Dis. 1983 Apr;147(4):751–757. doi: 10.1093/infdis/147.4.751. [DOI] [PubMed] [Google Scholar]
  7. Merrikin D. J., Briant J., Rolinson G. N. Effect of protein binding on antibiotic activity in vivo. J Antimicrob Chemother. 1983 Mar;11(3):233–238. doi: 10.1093/jac/11.3.233. [DOI] [PubMed] [Google Scholar]
  8. Miniter P. M., Patterson T. F., Johnson M. A., Andriole V. T. Activity of LY146032 in vitro and in experimental enterococcal pyelonephritis. Antimicrob Agents Chemother. 1987 Aug;31(8):1199–1203. doi: 10.1128/aac.31.8.1199. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Moellering R. C., Jr, Wennersten C., Medrek T., Weinberg A. N. Prevalence of high-level resistance to aminoglycosides in clinical isolates of enterococci. Antimicrob Agents Chemother (Bethesda) 1970;10:335–340. [PubMed] [Google Scholar]
  10. Murray B. E., Church D. A., Wanger A., Zscheck K., Levison M. E., Ingerman M. J., Abrutyn E., Mederski-Samoraj B. Comparison of two beta-lactamase-producing strains of Streptococcus faecalis. Antimicrob Agents Chemother. 1986 Dec;30(6):861–864. doi: 10.1128/aac.30.6.861. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Pien F. D., Williams R. D., Vosti K. L. Comparison of broth and human serum as the diluent in the serum bactericidal test. Antimicrob Agents Chemother. 1975 Jan;7(1):113–114. doi: 10.1128/aac.7.1.113. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Stratton C. W., Liu C., Ratner H. B., Weeks L. S. Bactericidal activity of deptomycin (LY146032) compared with those of ciprofloxacin, vancomycin, and ampicillin against enterococci as determined by kill-kinetic studies. Antimicrob Agents Chemother. 1987 Jul;31(7):1014–1016. doi: 10.1128/aac.31.7.1014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Wanger A. R., Murray B. E. Activity of LY146032 against Enterococci with and without high-level aminoglycoside resistance, including two penicillinase-producing strains. Antimicrob Agents Chemother. 1987 Nov;31(11):1779–1781. doi: 10.1128/aac.31.11.1779. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Watanakunakorn C., Bakie C. Synergism of vancomycin-gentamicin and vancomycin-streptomycin against enterococci. Antimicrob Agents Chemother. 1973 Aug;4(2):120–124. doi: 10.1128/aac.4.2.120. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Zervos M. J., Kauffman C. A., Therasse P. M., Bergman A. G., Mikesell T. S., Schaberg D. R. Nosocomial infection by gentamicin-resistant Streptococcus faecalis. An epidemiologic study. Ann Intern Med. 1987 May;106(5):687–691. doi: 10.7326/0003-4819-106-5-687. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES